ArticlePLoS computational biology2026
Structural mechanisms underlying distinct binding and activities of 18:0 and 18:1 lysophosphatidic acids at LPA1 receptor.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lysophosphatidic acids (LPAs) are bioactive lipids that regulate numerous physiological functions in humans. Cell signaling by LPAs is mediated mainly via six LPA receptors (LPA1-6), class A G protein-coupled receptors (GPCRs). Among these, LPA1 is recognized to play an essential role in cell proliferation, survival, migration, and tumorigenesis. Despite the structural similarity, 18:0-LPA and 18:1-LPA exhibit distinct functional responses in cell lines overexpressing LPA1. Specifically, our in vitro studies show that 18:1-LPA induces greater Erk activation than 18:0-LPA in PC-3 human prostate cancer cells. The structural basis underlying this differential receptor activation has not been previously studied. Using classical molecular dynamics and enhanced sampling techniques, we examined the access and binding mechanisms of the two LPA species to the active state LPA1 receptor. The results show that 18:0-LPA and 18:1-LPA adopt distinct and dynamic poses in the orthosteric pocket despite their similar starting configurations. Mainly, the alkyl chains of the ligands exhibit distinct orientations and residue interactions, leading to differential conformational changes in key activation switches on the conserved CWxP and PIF structural motifs of the receptor. Also, there are significant differences in interhelical interactions at the intracellular end of the transmembrane helices 1, 3, 6, and 7. These distinct arrangements lead to striking differences in LPA1 interactions with the Gα-helix of the heterotrimeric Gi-protein. Notably, 18:0-LPA and 18:1-LPA exhibit similar membrane partitioning characteristics and receptor entry processes through aqueous paths. Our comprehensive in-silico studies offer valuable structural insights into the observed differences in functional responses by 18:0- and 18:1-LPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.